AstraZeneca announces major investment and new partnership in China

The pharmaceutical company AstraZeneca has announced a significant new commitment to the Chinese market. The company plans to invest $15 billion in China and has formed a multibillion-dollar partnership with the Chinese firm CSPC Pharmaceuticals to develop new obesity and diabetes drugs.

AstraZeneca's CEO said investing in China is essential for the company's innovation efforts and that they plan to strengthen their cooperation there.